NYSE:ADCT

ADC Therapeutics Competitors

$23.21
-0.40 (-1.69 %)
(As of 04/16/2021 10:53 AM ET)
Add
Compare
Today's Range
$23.21
Now: $23.21
$23.77
50-Day Range
$22.73
MA: $25.73
$29.40
52-Week Range
$21.51
Now: $23.21
$56.59
Volume1,900 shs
Average Volume302,849 shs
Market Capitalization$1.60 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

ADC Therapeutics (NYSE:ADCT) Vs. TGTX, IONS, SRPT, ALLK, BPMC, and PRGO

Should you be buying ADCT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ADC Therapeutics, including TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Allakos (ALLK), Blueprint Medicines (BPMC), and Perrigo (PRGO).

TG Therapeutics (NASDAQ:TGTX) and ADC Therapeutics (NYSE:ADCT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for TG Therapeutics and ADC Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TG Therapeutics00503.00
ADC Therapeutics01402.80

TG Therapeutics currently has a consensus price target of $64.00, suggesting a potential upside of 39.37%. ADC Therapeutics has a consensus price target of $47.50, suggesting a potential upside of 104.65%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than TG Therapeutics.

Profitability

This table compares TG Therapeutics and ADC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TG Therapeutics-151,798.69%-223.96%-108.08%
ADC TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares TG Therapeutics and ADC Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$150,000.0043,038.06$-172,870,000.00($1.83)-25.09
ADC Therapeutics$2.34 million683.33$-116,480,000.00($2.36)-9.83

ADC Therapeutics has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

65.7% of TG Therapeutics shares are owned by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are owned by institutional investors. 13.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ADC Therapeutics beats TG Therapeutics on 7 of the 13 factors compared between the two stocks.

Ionis Pharmaceuticals (NASDAQ:IONS) and ADC Therapeutics (NYSE:ADCT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Ionis Pharmaceuticals and ADC Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ionis Pharmaceuticals27602.27
ADC Therapeutics01402.80

Ionis Pharmaceuticals currently has a consensus target price of $57.9091, suggesting a potential upside of 41.14%. ADC Therapeutics has a consensus target price of $47.50, suggesting a potential upside of 104.65%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Ionis Pharmaceuticals.

Earnings & Valuation

This table compares Ionis Pharmaceuticals and ADC Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$1.12 billion5.15$303.26 million$2.0819.73
ADC Therapeutics$2.34 million683.33$-116,480,000.00($2.36)-9.83

Ionis Pharmaceuticals has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ionis Pharmaceuticals and ADC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ionis Pharmaceuticals7.82%6.57%3.39%
ADC TherapeuticsN/AN/AN/A

Institutional and Insider Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Ionis Pharmaceuticals beats ADC Therapeutics on 10 of the 13 factors compared between the two stocks.

ADC Therapeutics (NYSE:ADCT) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Profitability

This table compares ADC Therapeutics and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADC TherapeuticsN/AN/AN/A
Sarepta Therapeutics-121.30%-61.62%-23.02%

Insider & Institutional Ownership

40.9% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares ADC Therapeutics and Sarepta Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADC Therapeutics$2.34 million683.33$-116,480,000.00($2.36)-9.83
Sarepta Therapeutics$380.83 million14.92$-715,080,000.00($9.71)-7.37

ADC Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for ADC Therapeutics and Sarepta Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADC Therapeutics01402.80
Sarepta Therapeutics191302.52

ADC Therapeutics currently has a consensus target price of $47.50, suggesting a potential upside of 104.65%. Sarepta Therapeutics has a consensus target price of $150.4762, suggesting a potential upside of 110.40%. Given Sarepta Therapeutics' higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than ADC Therapeutics.

Summary

ADC Therapeutics beats Sarepta Therapeutics on 7 of the 13 factors compared between the two stocks.

ADC Therapeutics (NYSE:ADCT) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Profitability

This table compares ADC Therapeutics and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADC TherapeuticsN/AN/AN/A
AllakosN/A-29.18%-27.70%

Analyst Recommendations

This is a summary of recent ratings for ADC Therapeutics and Allakos, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADC Therapeutics01402.80
Allakos00403.00

ADC Therapeutics currently has a consensus target price of $47.50, suggesting a potential upside of 104.65%. Allakos has a consensus target price of $181.50, suggesting a potential upside of 72.32%. Given ADC Therapeutics' higher probable upside, research analysts clearly believe ADC Therapeutics is more favorable than Allakos.

Valuation & Earnings

This table compares ADC Therapeutics and Allakos' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADC Therapeutics$2.34 million683.33$-116,480,000.00($2.36)-9.83
AllakosN/AN/A$-85,370,000.00($1.89)-55.73

Allakos has lower revenue, but higher earnings than ADC Therapeutics. Allakos is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

40.9% of ADC Therapeutics shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Blueprint Medicines (NASDAQ:BPMC) and ADC Therapeutics (NYSE:ADCT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares Blueprint Medicines and ADC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
ADC TherapeuticsN/AN/AN/A

Institutional & Insider Ownership

40.9% of ADC Therapeutics shares are held by institutional investors. 3.8% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Blueprint Medicines and ADC Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million83.61$-347,690,000.00($7.27)-13.20
ADC Therapeutics$2.34 million683.33$-116,480,000.00($2.36)-9.83

ADC Therapeutics has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Blueprint Medicines and ADC Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06812.67
ADC Therapeutics01402.80

Blueprint Medicines presently has a consensus target price of $112.40, indicating a potential upside of 17.14%. ADC Therapeutics has a consensus target price of $47.50, indicating a potential upside of 104.65%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Blueprint Medicines.

Summary

Blueprint Medicines beats ADC Therapeutics on 8 of the 14 factors compared between the two stocks.

ADC Therapeutics (NYSE:ADCT) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Institutional & Insider Ownership

40.9% of ADC Therapeutics shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares ADC Therapeutics and Perrigo's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADC Therapeutics$2.34 million683.33$-116,480,000.00($2.36)-9.83
Perrigo$4.84 billion1.15$146.10 million$4.0310.29

Perrigo has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for ADC Therapeutics and Perrigo, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADC Therapeutics01402.80
Perrigo04102.20

ADC Therapeutics presently has a consensus price target of $47.50, indicating a potential upside of 104.65%. Perrigo has a consensus price target of $52.00, indicating a potential upside of 25.36%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Perrigo.

Profitability

This table compares ADC Therapeutics and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADC TherapeuticsN/AN/AN/A
Perrigo-0.13%9.78%4.92%

Summary

Perrigo beats ADC Therapeutics on 7 of the 13 factors compared between the two stocks.


ADC Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.92-0.2%$6.44 billion$150,000.00-21.66Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.03-1.9%$5.78 billion$1.12 billion85.48
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.52-1.6%$5.77 billion$380.83 million-9.15Analyst Report
Allakos logo
ALLK
Allakos
1.7$105.33-2.7%$5.74 billionN/A-38.44Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.95-0.9%$5.56 billion$66.51 million17.70Analyst Report
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.5$41.48-0.7%$5.50 billion$4.84 billion-691.22
Schrödinger logo
SDGR
Schrödinger
1.3$78.18-0.2%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$78.95-0.6%$5.20 billion$1.00 billion-11.96Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.56-1.7%$4.70 billionN/A-6.08Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13-0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.06-1.1%$4.28 billion$204.89 million-36.33
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.11 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.08-1.4%$4.10 billion$806.43 million-9.50Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$76.06-2.1%$3.99 billion$1.11 billion24.46Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.28-1.4%$3.84 billion$117.91 million-11.01
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.83-2.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.74-4.7%$3.78 billionN/A-21.01Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.99-2.7%$3.60 billionN/A-6.20Analyst Report
Analyst Revision
News Coverage
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.11-1.3%$3.53 billion$114.62 million-7.71Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62-3.1%$3.47 billion$136.47 million-12.55
LEGN
Legend Biotech
1.2$25.40-1.6%$3.43 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14-0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96-1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.07-1.2%$3.34 billion$26.52 million-8.02
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.37-0.5%$3.29 billion$36.13 million-70.70
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$113.23-3.6%$3.17 billionN/A-56.33Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.65-0.6%$3.15 billion$1.17 billion-42.72
Arvinas logo
ARVN
Arvinas
1.5$62.57-0.7%$3.08 billion$42.98 million-24.44
MorphoSys logo
MOR
MorphoSys
0.3$22.75-1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.88-5.5%$2.91 billion$421.03 million22.14Analyst Report
Insider Selling
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.27-1.2%$2.89 billion$901.90 million-23.72
Organogenesis logo
ORGO
Organogenesis
1.0$21.22-6.5%$2.89 billion$260.98 million-353.67
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.43-1.3%$2.85 billion$644.77 million-10.76
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10-2.3%$2.73 billion$182.24 million-8.78Analyst Upgrade
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.18-4.5%$2.72 billion$25 million-9.04Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67-0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.50-2.0%$2.69 billion$306.49 million25.28
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.28-3.4%$2.62 billion$60,000.00-9.71
Xencor logo
XNCR
Xencor
1.2$42.78-4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88-1.1%$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76-3.6%$2.48 billion$15 million-17.68Unusual Options Activity
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.93-0.0%$2.47 billion$120.28 million-150.43Analyst Report
Decrease in Short Interest
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50-0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$50.89-4.0%$2.41 billion$33.94 million-87.74Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.96-0.2%$2.25 billion$963.01 million13.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.33-2.7%$2.18 billion$23.90 million-18.22Analyst Report
Unusual Options Activity
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$49.10-2.4%$2.06 billionN/A0.00Insider Selling
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$123.42-2.6%$2.03 billionN/A-11.15
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.07-4.0%$2.01 billion$410,000.00-5.88Analyst Report
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.52-2.2%$2.00 billion$103.54 million-19.19Insider Selling
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.